Physician profile
Armel Simo
NPI 1376708321
$6,889.94
in general payments reported to CMS, 2019-2025
22 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $745 · 2021: $799 · 2022: $943 · 2023: $1,089 · 2024: $945 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,039.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Viiv Healthcare Company | $1,648.90 | 2019-2025 | Cabenuva |
| Gilead Sciences, INC. | $1,265.01 | 2019-2025 | Descovy, Biktarvy, Sunlenca |
| Indivior INC. | $363.17 | 2019-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $251.79 | 2023-2025 | |
| Lilly USA, LLC | $236.64 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Nestle Healthcare Nutrition INC. | $222.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $158.00 | 2022 | |
| Novo Nordisk INC | $129.69 | 2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $123.48 | 2020 | |
| Exact Sciences Corporation | $113.72 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $68.88 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $67.64 | 2024 | |
| Amgen INC. | $56.25 | 2024-2025 | Krystexxa |
| Abbott Laboratories | $23.98 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.73 | 2020 | |
| Arbor Pharmaceuticals, INC. | $20.00 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.84 | 2022 | |
| Glaxosmithkline, LLC. | $19.08 | 2024 | Shingrix |
| Abbvie INC. | $15.64 | 2023 | Qulipta |
| Nevro Corp. | $14.34 | 2022 | |
| Merck Sharp & Dohme LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armel Simo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.